<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10629934</article-id>
    <article-id pub-id-type="pmid">37882750</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad659</article-id>
    <article-id pub-id-type="publisher-id">btad659</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genome Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ScanNeo2: a comprehensive workflow for neoantigen detection and immunogenicity prediction from diverse genomic and transcriptomic alterations</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9938-1920</contrib-id>
        <name>
          <surname>Schäfer</surname>
          <given-names>Richard A</given-names>
        </name>
        <aff><institution>Department of Urology, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL 60611, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3694-3428</contrib-id>
        <name>
          <surname>Guo</surname>
          <given-names>Qingxiang</given-names>
        </name>
        <aff><institution>Department of Urology, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL 60611, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9512-2240</contrib-id>
        <name>
          <surname>Yang</surname>
          <given-names>Rendong</given-names>
        </name>
        <aff><institution>Department of Urology, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL 60611, <country country="US">United States</country></aff>
        <aff><institution>Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL 60611, <country country="US">United States</country></aff>
        <xref rid="btad659-cor1" ref-type="corresp"/>
        <!--rendong.yang@northwestern.edu-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Kendziorski</surname>
          <given-names>Christina</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad659-cor1">Corresponding author. Department of Urology, Northwestern University Feinberg School of Medicine, 303 E Superior St, Chicago, IL 60611, United States. E-mail: <email>rendong.yang@northwestern.edu</email> (R.Y.)</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-10-26">
      <day>26</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>26</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>11</issue>
    <elocation-id>btad659</elocation-id>
    <history>
      <date date-type="received">
        <day>31</day>
        <month>7</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>10</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>20</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>24</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>02</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad659.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Neoantigens, tumor-specific protein fragments, are invaluable in cancer immunotherapy due to their ability to serve as targets for the immune system. Computational prediction of these neoantigens from sequencing data often requires multiple algorithms and sophisticated workflows, which are currently restricted to specific types of variants, such as single-nucleotide variants or insertions/deletions. Nevertheless, other sources of neoantigens are often overlooked.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We introduce <monospace>ScanNeo2</monospace> an improved and fully automated bioinformatics pipeline designed for high-throughput neoantigen prediction from raw sequencing data. Unlike its predecessor, ScanNeo2 integrates multiple sources of somatic variants, including canonical- and exitron-splicing, gene fusion events, and various somatic variants. Our benchmark results demonstrate that <monospace>ScanNeo2</monospace> accurately identifies neoantigens, providing a comprehensive and more efficient solution for neoantigen prediction.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p><monospace>ScanNeo2</monospace> is freely available at <ext-link xlink:href="https://github.com/ylab-hi/ScanNeo2/" ext-link-type="uri">https://github.com/ylab-hi/ScanNeo2/</ext-link> and is accompanied by instruction and application data.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health</institution>
            <institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R01CA259388</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Neoantigens are foreign protein fragments that originate from genetic mutations within cancer cells and are entirely absent in normal tissue. When presented on major histocompatibility complex (MHC) molecules, these neoepitopes can be recognized by CD4<inline-formula id="IE1"><mml:math id="IM1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> or CD8<inline-formula id="IE2"><mml:math id="IM2" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> T-cells. This can trigger an anti-cancer immune response in patients. However, cancer cells have developed resistance to anti-cancer immunity (<xref rid="btad659-B20" ref-type="bibr">Zhu <italic toggle="yes">et al.</italic> 2021</xref>). This effect can be reversed by cancer immunotherapies, which e.g. improve the presentation of neoepitopes. For that, tumor-specific neoantigens need to be identified to improve adoptive T-cell therapies. In the past, <monospace>ScanNeo</monospace> (<xref rid="btad659-B16" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2019</xref>) has been developed for detecting insertion and deletion (indel)-derived neoantigens and later combined with <monospace>ScanExitron</monospace> (<xref rid="btad659-B17" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2021</xref>) to detect neoantigens from exitron-derived events (<xref rid="btad659-B15" ref-type="bibr">Wang and Yang 2021</xref>). While several tools have been created to identify neoantigens from sequencing data, most focus mainly on finding neoantigens that come from single-nucleotide variants (SNVs), or indel events. But, they often overlook other sources of neoantigens like gene fusions or alternative splicing. In that regard, <monospace>pVACtools</monospace> (<xref rid="btad659-B6" ref-type="bibr">Hundal <italic toggle="yes">et al.</italic> 2020</xref>) provides a toolkit for neoantigen prediction and visualization, but requires a list of identified non-synonymous somatic variations identified by other pipelines. However, this requires the integration of multiple tools that need to be coordinated with one another. This can be simplified using workflow management systems, such as the <monospace>Nextflow</monospace> workflow language (<xref rid="btad659-B4" ref-type="bibr">Di Tommaso <italic toggle="yes">et al.</italic> 2017</xref>) or the <monospace>snakemake</monospace> workflow management system (<xref rid="btad659-B10" ref-type="bibr">Mölder <italic toggle="yes">et al.</italic> 2021</xref>). For instance, <monospace>nextNEOpi</monospace> (<xref rid="btad659-B11" ref-type="bibr">Rieder <italic toggle="yes">et al.</italic> 2022</xref>) presents a comprehensive workflow implemented in <monospace>Nextflow</monospace> but uses most routines from <monospace>pVACtools</monospace>. Features of existing workflows for the prediction of neoantigens are listed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>. To better address the complexity of coordinating tools and overcome these limitations, we present <monospace>ScanNeo2</monospace>. This advanced <monospace>snakemake</monospace> workflow is designed to discover neoantigens from a broader array of sources, offering a holistic and streamlined method to predict neoantigens from sequencing data.</p>
  </sec>
  <sec>
    <title>2 Results</title>
    <sec>
      <title>2.1 Neoantigen detection from multiple sources</title>
      <p>To date, various methods have been established for detecting genomic mutations and transcriptomic variants. We took advantage of those tools and developed a <monospace>snakemake</monospace>-based workflow for the detection of neoantigens from multiple sources, termed <monospace>ScanNeo2</monospace> (<xref rid="btad659-F1" ref-type="fig">Fig. 1</xref>). It takes as input both raw and processed WGS/WES data and/or RNA-seq data from normal/tumor samples. In addition, it also accepts a list of already identified variants in “Variant Call Format.” In principle, <monospace>ScanNeo2</monospace> consists of different steps described in the following. Based on the provided data, the sequencing reads can be pre-processed, which includes quality filtering or removal of adapter sequences. For that, <monospace>fastp</monospace> (<xref rid="btad659-B2" ref-type="bibr">Chen <italic toggle="yes">et al.</italic> 2018</xref>) is applied, and the reads are then subjected to the genotyping of HLA alleles and the mutation calling. In the former, DNA-seq and RNA-seq data are filtered for HLA reads using <monospace>yara</monospace> (<xref rid="btad659-B12" ref-type="bibr">Siragusa <italic toggle="yes">et al.</italic> 2013</xref>) and subsequently aligned against a panel of HLA class I alleles using <monospace>Optitype</monospace> (<xref rid="btad659-B13" ref-type="bibr">Szolek <italic toggle="yes">et al.</italic> 2014</xref>). This results in a list of detected 4-digit HLA genotypes that are later used in the prediction MHC class I antigen presentation. In a similar manner, <monospace>HLA-HD</monospace> (<xref rid="btad659-B8" ref-type="bibr">Kawaguchi <italic toggle="yes">et al.</italic> 2017</xref>) is used for HLA class II genotyping. In the following, the RNA-seq data are aligned against the reference genome using <monospace>BWA</monospace> (<xref rid="btad659-B9" ref-type="bibr">Li and Durbin 2009</xref>), and subsequently filtered for mapping quality, duplicates, and discarded of unmapped reads. In the mutation calling, the processed reads are subjected to <monospace>SplAdder</monospace> (<xref rid="btad659-B7" ref-type="bibr">Kahles <italic toggle="yes">et al.</italic> 2016</xref>) for the detection of alternative splicing events, and <monospace>ScanExitron</monospace> for identifying exitron-splicing events. In addition, <sc>gatk</sc> (<xref rid="btad659-B14" ref-type="bibr">Van der Auwera and O’Connor 2020</xref>) is utilized for detection of short indels, as well as SNVs. Here, the modules <monospace>mutect2</monospace>, and <monospace>haplotypecaller</monospace> are used for identifying somatic and germline variants, respectively. This is combined with <monospace>transIndel</monospace> (<xref rid="btad659-B19" ref-type="bibr">Yang <italic toggle="yes">et al.</italic> 2018</xref>) to detect long variants. <monospace>ScanNeo2</monospace> also incorporates gene fusion events. For that, the aligned reads are first realigned using <monospace>STAR</monospace> (<xref rid="btad659-B5" ref-type="bibr">Dobin <italic toggle="yes">et al.</italic> 2013</xref>), and then subjected to <monospace>Arriba</monospace> (<xref rid="btad659-B5" ref-type="bibr">Dobin <italic toggle="yes">et al.</italic> 2013</xref>). For the individual outputs of the respective tools, the (<ext-link xlink:href="https://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-0974-4?report=reader" ext-link-type="uri">VCF</ext-link>) is used to determine the downstream effects of the variants. In the case of a frameshift, only the transcripts are further considered that escape nonsense-mediated decay. The next step is to extract the amino acid sequence of the transcripts surrounding the variant. For that, peptides of different lengths are extracted that span the variants. This include peptides of length 8–11 and 13–25 amino acids, corresponding to MHC class I and MHC class II peptides, respectively. In the following, the Immune Epitope Database and Analysis Resource (IEDB) (<xref rid="btad659-B3" ref-type="bibr">Dhanda <italic toggle="yes">et al.</italic> 2019</xref>) is used to predict the T-cell epitope for MHC class I and II as well as the immunogenicity (<xref rid="btad659-B1" ref-type="bibr">Calis <italic toggle="yes">et al.</italic> 2013</xref>). This results in a tab-delimited list of predicted neoantigens.</p>
      <fig position="float" id="btad659-F1">
        <label>Figure 1.</label>
        <caption>
          <p>The workflow of ScanNeo2 is divided into three parts. In the first part, the input reads are prepared for the subsequent analysis, which includes the genotyping of the HLA alleles. In the next step, the variation calling is performed using the different modules canonical splicing, exitron, gene fusion, and indel/snp detection. This is concluded with the neoantigen prioritization.</p>
        </caption>
        <graphic xlink:href="btad659f1" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>2.2 Benchmarking using available datasets</title>
      <p><monospace>ScanNeo2</monospace> was assessed using the <monospace>TESLA</monospace> (<xref rid="btad659-B18" ref-type="bibr">Wells <italic toggle="yes">et al.</italic> 2020</xref>) dataset that contains data obtained from subjects (<italic toggle="yes">n</italic> = 8) in metastatic melanoma and non-small cell lung cancer. In that study, the authors tested 608 peptides for immunogenicity, of which 37 were found to be immunogenic. We analyzed the data using <monospace>ScanNeo2</monospace> (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Data</xref> for details), which included the data preparation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>) and identified in each patient 9152–96 819 putative HLA-binding peptides that account for unique peptides (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). Among those, 5671–34 981 candidate neoantigens originate from a single source, such as alternative splicing, exitron-splicing, gene fusion, indels, or SNVs. <monospace>ScanNeo2</monospace> detects 35 of the 37 experimentally validated immunogenic peptides but also captures 476 non-immunogenic peptides. In the following, we applied <monospace>ScanNeo2</monospace> with more stringent parameters (immunogenicity score <inline-formula id="IE3"><mml:math id="IM3" display="inline" overflow="scroll"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:math></inline-formula>, TPM <inline-formula id="IE4"><mml:math id="IM4" display="inline" overflow="scroll"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, ranking score <inline-formula id="IE5"><mml:math id="IM5" display="inline" overflow="scroll"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>1000</mml:mn></mml:mrow></mml:math></inline-formula>, and VAF <inline-formula id="IE6"><mml:math id="IM6" display="inline" overflow="scroll"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math></inline-formula>), which reduces the number of non-immunogenic peptides to 391 while retaining 34 of the validated peptides (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>). Similar settings in <monospace>nextNEOp</monospace> detects less immunogenic peptides. In addition, we looked at the runtime and memory requirements of <monospace>ScanNeo2</monospace>. In comparison to <monospace>nextNEOpi</monospace>, <monospace>ScanNeo2</monospace> requires on average <inline-formula id="IE7"><mml:math id="IM7" display="inline" overflow="scroll"><mml:mrow><mml:mo>∼</mml:mo><mml:mn>22.5</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> more CPU time. The main reason for that is the extensive variant calling in which multiple sources are used with high sensitivity.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Conclusion</title>
    <p>We introduce <monospace>ScanNeo2</monospace>, a comprehensive <monospace>snakemake</monospace>-based pipeline for predicting tumor neoepitopes from sequencing data. It has been implemented in <monospace>snakemake</monospace> to ensure ease of installation, usage as well as high portability. In contrast to other workflows, <monospace>ScanNeo2</monospace> incorporates multiple sources, thereby providing a means to decipher the neoantigen landscape to an unprecedented degree.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad659_Supplementary_Data</label>
      <media xlink:href="btad659_supplementary_data.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported in part by funds from the National Institutes of Health [NIH/NCI: R01CA259388].</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>WES and RNA-seq data used in this article are available in the Synapse platform, at <ext-link xlink:href="https://www.synapse.org/#!Synapse:syn21048999" ext-link-type="uri">https://www.synapse.org/#!Synapse:syn21048999</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad659-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Calis</surname><given-names>JJA</given-names></string-name>, <string-name><surname>Maybeno</surname><given-names>M</given-names></string-name>, <string-name><surname>Greenbaum</surname><given-names>JA</given-names></string-name></person-group><etal>et al</etal><article-title>Properties of MHC class I presented peptides that enhance immunogenicity</article-title>. <source>PLoS Comput Biol</source><year>2013</year>;<volume>9</volume>:<fpage>e1003266</fpage>.<pub-id pub-id-type="pmid">24204222</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name></person-group><etal>et al</etal><article-title>Fastp: an ultra-fast all-in-one FASTQ preprocessor</article-title>. <source>Bioinformatics</source><year>2018</year>;<volume>34</volume>:<fpage>i884</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">30423086</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dhanda</surname><given-names>SK</given-names></string-name>, <string-name><surname>Mahajan</surname><given-names>S</given-names></string-name>, <string-name><surname>Paul</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>IEDB-AR: immune epitope database—analysis resource in 2019</article-title>. <source>Nucleic Acids Res</source><year>2019</year>;<volume>47</volume>:<fpage>W502</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">31114900</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Tommaso</surname><given-names>P</given-names></string-name>, <string-name><surname>Chatzou</surname><given-names>M</given-names></string-name>, <string-name><surname>Floden</surname><given-names>EW</given-names></string-name></person-group><etal>et al</etal><article-title>Nextflow enables reproducible computational workflows</article-title>. <source>Nat Biotechnol</source><year>2017</year>;<volume>35</volume>:<fpage>316</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">28398311</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname><given-names>A</given-names></string-name>, <string-name><surname>Davis</surname><given-names>CA</given-names></string-name>, <string-name><surname>Schlesinger</surname><given-names>F</given-names></string-name></person-group><etal>et al</etal><article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source><year>2013</year>;<volume>29</volume>:<fpage>15</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hundal</surname><given-names>J</given-names></string-name>, <string-name><surname>Kiwala</surname><given-names>S</given-names></string-name>, <string-name><surname>McMichael</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>pVACtools: a computational toolkit to identify and visualize cancer neoantigens</article-title>. <source>Cancer Immunol Res</source><year>2020</year>;<volume>8</volume>:<fpage>409</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">31907209</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kahles</surname><given-names>A</given-names></string-name>, <string-name><surname>Ong</surname><given-names>CS</given-names></string-name>, <string-name><surname>Zhong</surname><given-names>Y</given-names></string-name></person-group><etal>et al</etal><article-title>SplAdder: identification, quantification and testing of alternative splicing events from RNA-Seq data</article-title>. <source>Bioinformatics</source><year>2016</year>;<volume>32</volume>:<fpage>1840</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">26873928</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kawaguchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Higasa</surname><given-names>K</given-names></string-name>, <string-name><surname>Shimizu</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>HLA-HD: an accurate HLA typing algorithm for next-generation sequencing data</article-title>. <source>Hum Mutat</source><year>2017</year>;<volume>38</volume>:<fpage>788</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">28419628</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>R.</given-names></string-name></person-group><article-title>Fast and accurate short read alignment with burrows–wheeler transform</article-title>. <source>Bioinformatics</source><year>2009</year>;<volume>25</volume>:<fpage>1754</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mölder</surname><given-names>F</given-names></string-name>, <string-name><surname>Jablonski</surname><given-names>KP</given-names></string-name>, <string-name><surname>Letcher</surname><given-names>B</given-names></string-name></person-group><etal>et al</etal><article-title>Sustainable data analysis with snakemake</article-title>. <source>F1000Res</source><year>2021</year>;<volume>10</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">34035898</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rieder</surname><given-names>D</given-names></string-name>, <string-name><surname>Fotakis</surname><given-names>G</given-names></string-name>, <string-name><surname>Ausserhofer</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>nextNEOpi: a comprehensive pipeline for computational neoantigen prediction</article-title>. <source>Bioinformatics</source><year>2022</year>;<volume>38</volume>:<fpage>1131</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">34788790</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siragusa</surname><given-names>E</given-names></string-name>, <string-name><surname>Weese</surname><given-names>D</given-names></string-name>, <string-name><surname>Reinert</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>Fast and accurate read mapping with approximate seeds and multiple backtracking</article-title>. <source>Nucleic Acids Res</source><year>2013</year>;<volume>41</volume>:<fpage>e78</fpage>.<pub-id pub-id-type="pmid">23358824</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szolek</surname><given-names>A</given-names></string-name>, <string-name><surname>Schubert</surname><given-names>B</given-names></string-name>, <string-name><surname>Mohr</surname><given-names>C</given-names></string-name></person-group><etal>et al</etal><article-title>OptiType: precision HLA typing from next-generation sequencing data</article-title>. <source>Bioinformatics</source><year>2014</year>;<volume>30</volume>:<fpage>3310</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">25143287</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B14">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Van der Auwera</surname><given-names>GA</given-names></string-name>, <string-name><surname>O’Connor</surname><given-names>BD.</given-names></string-name></person-group><source>Genomics in the Cloud</source>. <publisher-loc>Sebastopol, CA, USA</publisher-loc>: <publisher-name>O’Reilly Media, Inc</publisher-name>., <year>2020</year>.</mixed-citation>
    </ref>
    <ref id="btad659-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T-Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Ren</surname><given-names>Y</given-names></string-name></person-group><etal>et al</etal><article-title>A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes</article-title>. <source>Mol Cell</source><year>2021</year>;<volume>81</volume>:<fpage>2246</fpage>–<lpage>60.e12</lpage>.<pub-id pub-id-type="pmid">33861991</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T-Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Alam</surname><given-names>SK</given-names></string-name></person-group><etal>et al</etal><article-title>ScanNeo: identifying indel-derived neoantigens using RNA-Seq data</article-title>. <source>Bioinformatics</source><year>2019</year>;<volume>35</volume>:<fpage>4159</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">30887025</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>R.</given-names></string-name></person-group><article-title>Integrated protocol for exitron and exitron-derived neoantigen identification using human RNA-seq data with ScanExitron and ScanNeo</article-title>. <source>STAR Protoc</source><year>2021</year>;<volume>2</volume>:<fpage>100788</fpage>.<pub-id pub-id-type="pmid">34522901</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wells</surname><given-names>DK</given-names></string-name>, <string-name><surname>van Buuren</surname><given-names>MM</given-names></string-name>, <string-name><surname>Dang</surname><given-names>KK</given-names></string-name></person-group><etal>et al</etal>; <collab>Tumor Neoantigen Selection Alliance</collab>. <article-title>Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction</article-title>. <source>Cell</source><year>2020</year>;<volume>183</volume>:<fpage>818</fpage>–<lpage>34.e13</lpage>.<pub-id pub-id-type="pmid">33038342</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>R</given-names></string-name>, <string-name><surname>Van Etten</surname><given-names>JL</given-names></string-name>, <string-name><surname>Dehm</surname><given-names>SM</given-names></string-name></person-group><etal>et al</etal><article-title>Indel detection from DNA and RNA sequencing data with transIndel</article-title>. <source>BMC Genomics</source><year>2018</year>;<volume>19</volume>:<fpage>270</fpage>.<pub-id pub-id-type="pmid">29673323</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>L</given-names></string-name></person-group><etal>et al</etal><article-title>Combination strategies to maximize the benefits of cancer immunotherapy</article-title>. <source>J Hematol Oncol</source><year>2021</year>;<volume>14</volume>:<fpage>156</fpage>.<pub-id pub-id-type="pmid">34579759</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10629934</article-id>
    <article-id pub-id-type="pmid">37882750</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad659</article-id>
    <article-id pub-id-type="publisher-id">btad659</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genome Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ScanNeo2: a comprehensive workflow for neoantigen detection and immunogenicity prediction from diverse genomic and transcriptomic alterations</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9938-1920</contrib-id>
        <name>
          <surname>Schäfer</surname>
          <given-names>Richard A</given-names>
        </name>
        <aff><institution>Department of Urology, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL 60611, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3694-3428</contrib-id>
        <name>
          <surname>Guo</surname>
          <given-names>Qingxiang</given-names>
        </name>
        <aff><institution>Department of Urology, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL 60611, <country country="US">United States</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9512-2240</contrib-id>
        <name>
          <surname>Yang</surname>
          <given-names>Rendong</given-names>
        </name>
        <aff><institution>Department of Urology, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL 60611, <country country="US">United States</country></aff>
        <aff><institution>Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine</institution>, Chicago, IL 60611, <country country="US">United States</country></aff>
        <xref rid="btad659-cor1" ref-type="corresp"/>
        <!--rendong.yang@northwestern.edu-->
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Kendziorski</surname>
          <given-names>Christina</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad659-cor1">Corresponding author. Department of Urology, Northwestern University Feinberg School of Medicine, 303 E Superior St, Chicago, IL 60611, United States. E-mail: <email>rendong.yang@northwestern.edu</email> (R.Y.)</corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-10-26">
      <day>26</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>26</day>
      <month>10</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>11</issue>
    <elocation-id>btad659</elocation-id>
    <history>
      <date date-type="received">
        <day>31</day>
        <month>7</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>10</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>20</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>24</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>02</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad659.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Motivation</title>
        <p>Neoantigens, tumor-specific protein fragments, are invaluable in cancer immunotherapy due to their ability to serve as targets for the immune system. Computational prediction of these neoantigens from sequencing data often requires multiple algorithms and sophisticated workflows, which are currently restricted to specific types of variants, such as single-nucleotide variants or insertions/deletions. Nevertheless, other sources of neoantigens are often overlooked.</p>
      </sec>
      <sec id="s2">
        <title>Results</title>
        <p>We introduce <monospace>ScanNeo2</monospace> an improved and fully automated bioinformatics pipeline designed for high-throughput neoantigen prediction from raw sequencing data. Unlike its predecessor, ScanNeo2 integrates multiple sources of somatic variants, including canonical- and exitron-splicing, gene fusion events, and various somatic variants. Our benchmark results demonstrate that <monospace>ScanNeo2</monospace> accurately identifies neoantigens, providing a comprehensive and more efficient solution for neoantigen prediction.</p>
      </sec>
      <sec id="s3">
        <title>Availability and implementation</title>
        <p><monospace>ScanNeo2</monospace> is freely available at <ext-link xlink:href="https://github.com/ylab-hi/ScanNeo2/" ext-link-type="uri">https://github.com/ylab-hi/ScanNeo2/</ext-link> and is accompanied by instruction and application data.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health</institution>
            <institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>R01CA259388</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Neoantigens are foreign protein fragments that originate from genetic mutations within cancer cells and are entirely absent in normal tissue. When presented on major histocompatibility complex (MHC) molecules, these neoepitopes can be recognized by CD4<inline-formula id="IE1"><mml:math id="IM1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> or CD8<inline-formula id="IE2"><mml:math id="IM2" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow/><mml:mo>+</mml:mo></mml:msup></mml:mrow></mml:mrow></mml:math></inline-formula> T-cells. This can trigger an anti-cancer immune response in patients. However, cancer cells have developed resistance to anti-cancer immunity (<xref rid="btad659-B20" ref-type="bibr">Zhu <italic toggle="yes">et al.</italic> 2021</xref>). This effect can be reversed by cancer immunotherapies, which e.g. improve the presentation of neoepitopes. For that, tumor-specific neoantigens need to be identified to improve adoptive T-cell therapies. In the past, <monospace>ScanNeo</monospace> (<xref rid="btad659-B16" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2019</xref>) has been developed for detecting insertion and deletion (indel)-derived neoantigens and later combined with <monospace>ScanExitron</monospace> (<xref rid="btad659-B17" ref-type="bibr">Wang <italic toggle="yes">et al.</italic> 2021</xref>) to detect neoantigens from exitron-derived events (<xref rid="btad659-B15" ref-type="bibr">Wang and Yang 2021</xref>). While several tools have been created to identify neoantigens from sequencing data, most focus mainly on finding neoantigens that come from single-nucleotide variants (SNVs), or indel events. But, they often overlook other sources of neoantigens like gene fusions or alternative splicing. In that regard, <monospace>pVACtools</monospace> (<xref rid="btad659-B6" ref-type="bibr">Hundal <italic toggle="yes">et al.</italic> 2020</xref>) provides a toolkit for neoantigen prediction and visualization, but requires a list of identified non-synonymous somatic variations identified by other pipelines. However, this requires the integration of multiple tools that need to be coordinated with one another. This can be simplified using workflow management systems, such as the <monospace>Nextflow</monospace> workflow language (<xref rid="btad659-B4" ref-type="bibr">Di Tommaso <italic toggle="yes">et al.</italic> 2017</xref>) or the <monospace>snakemake</monospace> workflow management system (<xref rid="btad659-B10" ref-type="bibr">Mölder <italic toggle="yes">et al.</italic> 2021</xref>). For instance, <monospace>nextNEOpi</monospace> (<xref rid="btad659-B11" ref-type="bibr">Rieder <italic toggle="yes">et al.</italic> 2022</xref>) presents a comprehensive workflow implemented in <monospace>Nextflow</monospace> but uses most routines from <monospace>pVACtools</monospace>. Features of existing workflows for the prediction of neoantigens are listed in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>. To better address the complexity of coordinating tools and overcome these limitations, we present <monospace>ScanNeo2</monospace>. This advanced <monospace>snakemake</monospace> workflow is designed to discover neoantigens from a broader array of sources, offering a holistic and streamlined method to predict neoantigens from sequencing data.</p>
  </sec>
  <sec>
    <title>2 Results</title>
    <sec>
      <title>2.1 Neoantigen detection from multiple sources</title>
      <p>To date, various methods have been established for detecting genomic mutations and transcriptomic variants. We took advantage of those tools and developed a <monospace>snakemake</monospace>-based workflow for the detection of neoantigens from multiple sources, termed <monospace>ScanNeo2</monospace> (<xref rid="btad659-F1" ref-type="fig">Fig. 1</xref>). It takes as input both raw and processed WGS/WES data and/or RNA-seq data from normal/tumor samples. In addition, it also accepts a list of already identified variants in “Variant Call Format.” In principle, <monospace>ScanNeo2</monospace> consists of different steps described in the following. Based on the provided data, the sequencing reads can be pre-processed, which includes quality filtering or removal of adapter sequences. For that, <monospace>fastp</monospace> (<xref rid="btad659-B2" ref-type="bibr">Chen <italic toggle="yes">et al.</italic> 2018</xref>) is applied, and the reads are then subjected to the genotyping of HLA alleles and the mutation calling. In the former, DNA-seq and RNA-seq data are filtered for HLA reads using <monospace>yara</monospace> (<xref rid="btad659-B12" ref-type="bibr">Siragusa <italic toggle="yes">et al.</italic> 2013</xref>) and subsequently aligned against a panel of HLA class I alleles using <monospace>Optitype</monospace> (<xref rid="btad659-B13" ref-type="bibr">Szolek <italic toggle="yes">et al.</italic> 2014</xref>). This results in a list of detected 4-digit HLA genotypes that are later used in the prediction MHC class I antigen presentation. In a similar manner, <monospace>HLA-HD</monospace> (<xref rid="btad659-B8" ref-type="bibr">Kawaguchi <italic toggle="yes">et al.</italic> 2017</xref>) is used for HLA class II genotyping. In the following, the RNA-seq data are aligned against the reference genome using <monospace>BWA</monospace> (<xref rid="btad659-B9" ref-type="bibr">Li and Durbin 2009</xref>), and subsequently filtered for mapping quality, duplicates, and discarded of unmapped reads. In the mutation calling, the processed reads are subjected to <monospace>SplAdder</monospace> (<xref rid="btad659-B7" ref-type="bibr">Kahles <italic toggle="yes">et al.</italic> 2016</xref>) for the detection of alternative splicing events, and <monospace>ScanExitron</monospace> for identifying exitron-splicing events. In addition, <sc>gatk</sc> (<xref rid="btad659-B14" ref-type="bibr">Van der Auwera and O’Connor 2020</xref>) is utilized for detection of short indels, as well as SNVs. Here, the modules <monospace>mutect2</monospace>, and <monospace>haplotypecaller</monospace> are used for identifying somatic and germline variants, respectively. This is combined with <monospace>transIndel</monospace> (<xref rid="btad659-B19" ref-type="bibr">Yang <italic toggle="yes">et al.</italic> 2018</xref>) to detect long variants. <monospace>ScanNeo2</monospace> also incorporates gene fusion events. For that, the aligned reads are first realigned using <monospace>STAR</monospace> (<xref rid="btad659-B5" ref-type="bibr">Dobin <italic toggle="yes">et al.</italic> 2013</xref>), and then subjected to <monospace>Arriba</monospace> (<xref rid="btad659-B5" ref-type="bibr">Dobin <italic toggle="yes">et al.</italic> 2013</xref>). For the individual outputs of the respective tools, the (<ext-link xlink:href="https://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-0974-4?report=reader" ext-link-type="uri">VCF</ext-link>) is used to determine the downstream effects of the variants. In the case of a frameshift, only the transcripts are further considered that escape nonsense-mediated decay. The next step is to extract the amino acid sequence of the transcripts surrounding the variant. For that, peptides of different lengths are extracted that span the variants. This include peptides of length 8–11 and 13–25 amino acids, corresponding to MHC class I and MHC class II peptides, respectively. In the following, the Immune Epitope Database and Analysis Resource (IEDB) (<xref rid="btad659-B3" ref-type="bibr">Dhanda <italic toggle="yes">et al.</italic> 2019</xref>) is used to predict the T-cell epitope for MHC class I and II as well as the immunogenicity (<xref rid="btad659-B1" ref-type="bibr">Calis <italic toggle="yes">et al.</italic> 2013</xref>). This results in a tab-delimited list of predicted neoantigens.</p>
      <fig position="float" id="btad659-F1">
        <label>Figure 1.</label>
        <caption>
          <p>The workflow of ScanNeo2 is divided into three parts. In the first part, the input reads are prepared for the subsequent analysis, which includes the genotyping of the HLA alleles. In the next step, the variation calling is performed using the different modules canonical splicing, exitron, gene fusion, and indel/snp detection. This is concluded with the neoantigen prioritization.</p>
        </caption>
        <graphic xlink:href="btad659f1" position="float"/>
      </fig>
    </sec>
    <sec>
      <title>2.2 Benchmarking using available datasets</title>
      <p><monospace>ScanNeo2</monospace> was assessed using the <monospace>TESLA</monospace> (<xref rid="btad659-B18" ref-type="bibr">Wells <italic toggle="yes">et al.</italic> 2020</xref>) dataset that contains data obtained from subjects (<italic toggle="yes">n</italic> = 8) in metastatic melanoma and non-small cell lung cancer. In that study, the authors tested 608 peptides for immunogenicity, of which 37 were found to be immunogenic. We analyzed the data using <monospace>ScanNeo2</monospace> (see <xref rid="sup1" ref-type="supplementary-material">Supplementary Data</xref> for details), which included the data preparation (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>) and identified in each patient 9152–96 819 putative HLA-binding peptides that account for unique peptides (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). Among those, 5671–34 981 candidate neoantigens originate from a single source, such as alternative splicing, exitron-splicing, gene fusion, indels, or SNVs. <monospace>ScanNeo2</monospace> detects 35 of the 37 experimentally validated immunogenic peptides but also captures 476 non-immunogenic peptides. In the following, we applied <monospace>ScanNeo2</monospace> with more stringent parameters (immunogenicity score <inline-formula id="IE3"><mml:math id="IM3" display="inline" overflow="scroll"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:math></inline-formula>, TPM <inline-formula id="IE4"><mml:math id="IM4" display="inline" overflow="scroll"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>, ranking score <inline-formula id="IE5"><mml:math id="IM5" display="inline" overflow="scroll"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>1000</mml:mn></mml:mrow></mml:math></inline-formula>, and VAF <inline-formula id="IE6"><mml:math id="IM6" display="inline" overflow="scroll"><mml:mrow><mml:mo>≥</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math></inline-formula>), which reduces the number of non-immunogenic peptides to 391 while retaining 34 of the validated peptides (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>). Similar settings in <monospace>nextNEOp</monospace> detects less immunogenic peptides. In addition, we looked at the runtime and memory requirements of <monospace>ScanNeo2</monospace>. In comparison to <monospace>nextNEOpi</monospace>, <monospace>ScanNeo2</monospace> requires on average <inline-formula id="IE7"><mml:math id="IM7" display="inline" overflow="scroll"><mml:mrow><mml:mo>∼</mml:mo><mml:mn>22.5</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula> more CPU time. The main reason for that is the extensive variant calling in which multiple sources are used with high sensitivity.</p>
    </sec>
  </sec>
  <sec>
    <title>3 Conclusion</title>
    <p>We introduce <monospace>ScanNeo2</monospace>, a comprehensive <monospace>snakemake</monospace>-based pipeline for predicting tumor neoepitopes from sequencing data. It has been implemented in <monospace>snakemake</monospace> to ensure ease of installation, usage as well as high portability. In contrast to other workflows, <monospace>ScanNeo2</monospace> incorporates multiple sources, thereby providing a means to decipher the neoantigen landscape to an unprecedented degree.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad659_Supplementary_Data</label>
      <media xlink:href="btad659_supplementary_data.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec>
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflict of interest</title>
    <p>None declared.</p>
  </sec>
  <sec>
    <title>Funding</title>
    <p>This work was supported in part by funds from the National Institutes of Health [NIH/NCI: R01CA259388].</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>WES and RNA-seq data used in this article are available in the Synapse platform, at <ext-link xlink:href="https://www.synapse.org/#!Synapse:syn21048999" ext-link-type="uri">https://www.synapse.org/#!Synapse:syn21048999</ext-link>.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad659-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Calis</surname><given-names>JJA</given-names></string-name>, <string-name><surname>Maybeno</surname><given-names>M</given-names></string-name>, <string-name><surname>Greenbaum</surname><given-names>JA</given-names></string-name></person-group><etal>et al</etal><article-title>Properties of MHC class I presented peptides that enhance immunogenicity</article-title>. <source>PLoS Comput Biol</source><year>2013</year>;<volume>9</volume>:<fpage>e1003266</fpage>.<pub-id pub-id-type="pmid">24204222</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name></person-group><etal>et al</etal><article-title>Fastp: an ultra-fast all-in-one FASTQ preprocessor</article-title>. <source>Bioinformatics</source><year>2018</year>;<volume>34</volume>:<fpage>i884</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">30423086</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dhanda</surname><given-names>SK</given-names></string-name>, <string-name><surname>Mahajan</surname><given-names>S</given-names></string-name>, <string-name><surname>Paul</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>IEDB-AR: immune epitope database—analysis resource in 2019</article-title>. <source>Nucleic Acids Res</source><year>2019</year>;<volume>47</volume>:<fpage>W502</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">31114900</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Tommaso</surname><given-names>P</given-names></string-name>, <string-name><surname>Chatzou</surname><given-names>M</given-names></string-name>, <string-name><surname>Floden</surname><given-names>EW</given-names></string-name></person-group><etal>et al</etal><article-title>Nextflow enables reproducible computational workflows</article-title>. <source>Nat Biotechnol</source><year>2017</year>;<volume>35</volume>:<fpage>316</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">28398311</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname><given-names>A</given-names></string-name>, <string-name><surname>Davis</surname><given-names>CA</given-names></string-name>, <string-name><surname>Schlesinger</surname><given-names>F</given-names></string-name></person-group><etal>et al</etal><article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source><year>2013</year>;<volume>29</volume>:<fpage>15</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">23104886</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hundal</surname><given-names>J</given-names></string-name>, <string-name><surname>Kiwala</surname><given-names>S</given-names></string-name>, <string-name><surname>McMichael</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>pVACtools: a computational toolkit to identify and visualize cancer neoantigens</article-title>. <source>Cancer Immunol Res</source><year>2020</year>;<volume>8</volume>:<fpage>409</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">31907209</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kahles</surname><given-names>A</given-names></string-name>, <string-name><surname>Ong</surname><given-names>CS</given-names></string-name>, <string-name><surname>Zhong</surname><given-names>Y</given-names></string-name></person-group><etal>et al</etal><article-title>SplAdder: identification, quantification and testing of alternative splicing events from RNA-Seq data</article-title>. <source>Bioinformatics</source><year>2016</year>;<volume>32</volume>:<fpage>1840</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">26873928</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kawaguchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Higasa</surname><given-names>K</given-names></string-name>, <string-name><surname>Shimizu</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>HLA-HD: an accurate HLA typing algorithm for next-generation sequencing data</article-title>. <source>Hum Mutat</source><year>2017</year>;<volume>38</volume>:<fpage>788</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">28419628</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Durbin</surname><given-names>R.</given-names></string-name></person-group><article-title>Fast and accurate short read alignment with burrows–wheeler transform</article-title>. <source>Bioinformatics</source><year>2009</year>;<volume>25</volume>:<fpage>1754</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mölder</surname><given-names>F</given-names></string-name>, <string-name><surname>Jablonski</surname><given-names>KP</given-names></string-name>, <string-name><surname>Letcher</surname><given-names>B</given-names></string-name></person-group><etal>et al</etal><article-title>Sustainable data analysis with snakemake</article-title>. <source>F1000Res</source><year>2021</year>;<volume>10</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">34035898</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rieder</surname><given-names>D</given-names></string-name>, <string-name><surname>Fotakis</surname><given-names>G</given-names></string-name>, <string-name><surname>Ausserhofer</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>nextNEOpi: a comprehensive pipeline for computational neoantigen prediction</article-title>. <source>Bioinformatics</source><year>2022</year>;<volume>38</volume>:<fpage>1131</fpage>–<lpage>2</lpage>.<pub-id pub-id-type="pmid">34788790</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siragusa</surname><given-names>E</given-names></string-name>, <string-name><surname>Weese</surname><given-names>D</given-names></string-name>, <string-name><surname>Reinert</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>Fast and accurate read mapping with approximate seeds and multiple backtracking</article-title>. <source>Nucleic Acids Res</source><year>2013</year>;<volume>41</volume>:<fpage>e78</fpage>.<pub-id pub-id-type="pmid">23358824</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Szolek</surname><given-names>A</given-names></string-name>, <string-name><surname>Schubert</surname><given-names>B</given-names></string-name>, <string-name><surname>Mohr</surname><given-names>C</given-names></string-name></person-group><etal>et al</etal><article-title>OptiType: precision HLA typing from next-generation sequencing data</article-title>. <source>Bioinformatics</source><year>2014</year>;<volume>30</volume>:<fpage>3310</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">25143287</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B14">
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Van der Auwera</surname><given-names>GA</given-names></string-name>, <string-name><surname>O’Connor</surname><given-names>BD.</given-names></string-name></person-group><source>Genomics in the Cloud</source>. <publisher-loc>Sebastopol, CA, USA</publisher-loc>: <publisher-name>O’Reilly Media, Inc</publisher-name>., <year>2020</year>.</mixed-citation>
    </ref>
    <ref id="btad659-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T-Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Ren</surname><given-names>Y</given-names></string-name></person-group><etal>et al</etal><article-title>A pan-cancer transcriptome analysis of exitron splicing identifies novel cancer driver genes and neoepitopes</article-title>. <source>Mol Cell</source><year>2021</year>;<volume>81</volume>:<fpage>2246</fpage>–<lpage>60.e12</lpage>.<pub-id pub-id-type="pmid">33861991</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T-Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Alam</surname><given-names>SK</given-names></string-name></person-group><etal>et al</etal><article-title>ScanNeo: identifying indel-derived neoantigens using RNA-Seq data</article-title>. <source>Bioinformatics</source><year>2019</year>;<volume>35</volume>:<fpage>4159</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">30887025</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>T-Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>R.</given-names></string-name></person-group><article-title>Integrated protocol for exitron and exitron-derived neoantigen identification using human RNA-seq data with ScanExitron and ScanNeo</article-title>. <source>STAR Protoc</source><year>2021</year>;<volume>2</volume>:<fpage>100788</fpage>.<pub-id pub-id-type="pmid">34522901</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wells</surname><given-names>DK</given-names></string-name>, <string-name><surname>van Buuren</surname><given-names>MM</given-names></string-name>, <string-name><surname>Dang</surname><given-names>KK</given-names></string-name></person-group><etal>et al</etal>; <collab>Tumor Neoantigen Selection Alliance</collab>. <article-title>Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction</article-title>. <source>Cell</source><year>2020</year>;<volume>183</volume>:<fpage>818</fpage>–<lpage>34.e13</lpage>.<pub-id pub-id-type="pmid">33038342</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B19">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>R</given-names></string-name>, <string-name><surname>Van Etten</surname><given-names>JL</given-names></string-name>, <string-name><surname>Dehm</surname><given-names>SM</given-names></string-name></person-group><etal>et al</etal><article-title>Indel detection from DNA and RNA sequencing data with transIndel</article-title>. <source>BMC Genomics</source><year>2018</year>;<volume>19</volume>:<fpage>270</fpage>.<pub-id pub-id-type="pmid">29673323</pub-id></mixed-citation>
    </ref>
    <ref id="btad659-B20">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>T</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>L</given-names></string-name></person-group><etal>et al</etal><article-title>Combination strategies to maximize the benefits of cancer immunotherapy</article-title>. <source>J Hematol Oncol</source><year>2021</year>;<volume>14</volume>:<fpage>156</fpage>.<pub-id pub-id-type="pmid">34579759</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
